HomeCompareDRNA vs EPRT

DRNA vs EPRT: Dividend Comparison 2026

DRNA yields 5.23% · EPRT yields 3.97%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPRT wins by $36.1K in total portfolio value· pulled ahead in Year 2
10 years
DRNA
DRNA
● Live price
5.23%
Share price
$38.22
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.2K
Annual income
$731.12
Full DRNA calculator →
EPRT
EPRT
● Live price
3.97%
Share price
$30.36
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.3K
Annual income
$13,170.85
Full EPRT calculator →

Portfolio growth — DRNA vs EPRT

📍 EPRT pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDRNAEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DRNA + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DRNA pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DRNA
Annual income on $10K today (after 15% tax)
$444.79/yr
After 10yr DRIP, annual income (after tax)
$621.45/yr
EPRT
Annual income on $10K today (after 15% tax)
$337.37/yr
After 10yr DRIP, annual income (after tax)
$11,195.22/yr
At 15% tax rate, EPRT beats the other by $10,573.77/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DRNA + EPRT for your $10,000?

DRNA: 50%EPRT: 50%
100% EPRT50/50100% DRNA
Portfolio after 10yr
$46.3K
Annual income
$6,950.99/yr
Blended yield
15.02%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

DRNA
Analyst Ratings
11
Buy
6
Hold
Consensus: Buy
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+16.9% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DRNA buys
0
EPRT buys
0
No recent congressional trades found for DRNA or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDRNAEPRT
Forward yield5.23%3.97%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$28.2K$64.3K
Annual income after 10y$731.12$13,170.85
Total dividends collected$6.3K$38.7K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: DRNA vs EPRT ($10,000, DRIP)

YearDRNA PortfolioDRNA Income/yrEPRT PortfolioEPRT Income/yrGap
1$11,223$523.29$11,212$512.01+$11.00DRNA
2← crossover$12,558$548.88$12,689$692.09$131.00EPRT
3$14,011$573.96$14,521$944.30$510.00EPRT
4$15,590$598.48$16,841$1,302.88$1.3KEPRT
5$17,304$622.37$19,841$1,821.64$2.5KEPRT
6$19,161$645.59$23,818$2,587.47$4.7KEPRT
7$21,170$668.11$29,230$3,744.65$8.1KEPRT
8$23,342$689.88$36,816$5,540.38$13.5KEPRT
9$25,686$710.89$47,806$8,413.17$22.1KEPRT
10$28,216$731.12$64,324$13,170.85$36.1KEPRT

DRNA vs EPRT: Complete Analysis 2026

DRNAStock

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. As of December 27, 2021, Dicerna Pharmaceuticals, Inc. operates as a subsidiary of Novo Nordisk A/S.

Full DRNA Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this DRNA vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DRNA vs SCHDDRNA vs JEPIDRNA vs ODRNA vs KODRNA vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.